Literature DB >> 16648569

DNA adducts formed by a novel antitumor agent 11beta-dichloro in vitro and in vivo.

Shawn M Hillier1, John C Marquis, Beatriz Zayas, John S Wishnok, Rosa G Liberman, Paul L Skipper, Steven R Tannenbaum, John M Essigmann, Robert G Croy.   

Abstract

The multifunctional molecule 11beta-dichloro consists of a ligand for the androgen receptor linked to a bifunctional alkylating group, permitting it to create DNA adducts that bind the androgen receptor. We propose that binding of the androgen receptor to 11beta-DNA adducts acts to both shield damaged sites from repair and disrupt the expression of genes essential for growth and survival. We investigated the formation 11beta-DNA adducts in tumor xenograft and nontumor tissues in mice. Using [14C]-11beta-dichloro, we show that the molecule remains intact in blood and is widely distributed in mouse tissues after i.p. injection. Covalent 11beta-guanine adducts identified in DNA that had been allowed to react with 11beta-dichloro in vitro were also found in DNA isolated from cells in culture treated with 11beta-dichloro as well as in DNA isolated from liver and tumor tissues of mice treated with the compound. We used accelerator mass spectrometry to determine the levels of [14C]-11beta-DNA adducts in LNCaP cells treated in culture as well as in liver tissue and LNCaP xenograft tumors in treated mice. The level of DNA adducts in tumor tissue was found to be similar to that found in LNCaP cells in culture treated with 2.5 micromol/L 11beta-dichloro. Our results indicate that 11beta-dichloro has sufficient stability to enter the circulation, penetrate tissues, and form DNA adducts that are capable of binding the androgen receptor in target tissues in vivo. These data suggest the involvement of our novel mechanisms in the antitumor effects of 11beta-dichloro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648569     DOI: 10.1158/1535-7163.MCT-05-0464

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  7 in total

Review 1.  Accelerator mass spectrometry-enabled studies: current status and future prospects.

Authors:  Ali Arjomand
Journal:  Bioanalysis       Date:  2010-03       Impact factor: 2.681

2.  Chemical genetics analysis of an aniline mustard anticancer agent reveals complex I of the electron transport chain as a target.

Authors:  Bogdan I Fedeles; Angela Y Zhu; Kellie S Young; Shawn M Hillier; Kyle D Proffitt; John M Essigmann; Robert G Croy
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

3.  Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs.

Authors:  Yunyan Kuang; Kumudha Balakrishnan; Varsha Gandhi; Xiaohua Peng
Journal:  J Am Chem Soc       Date:  2011-11-10       Impact factor: 15.419

4.  Human microdosing for the prediction of patient response.

Authors:  Paul T Henderson; Chong-Xian Pan
Journal:  Bioanalysis       Date:  2010-03       Impact factor: 2.681

5.  Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.

Authors:  Nicolette A Louissaint; Ying-Jun Cao; Paul L Skipper; Rosa G Liberman; Steven R Tannenbaum; Sridhar Nimmagadda; Jean R Anderson; Stephanie Everts; Rahul Bakshi; Edward J Fuchs; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-29       Impact factor: 2.205

6.  An investigation into pharmaceutically relevant mutagenicity data and the influence on Ames predictive potential.

Authors:  Patrick McCarren; Clayton Springer; Lewis Whitehead
Journal:  J Cheminform       Date:  2011-11-22       Impact factor: 5.514

7.  Dietary feeding of Flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in mice.

Authors:  Xuesen Li; Xia Xu; Tao Ji; Zhongbo Liu; Mai Gu; Bang H Hoang; Xiaolin Zi
Journal:  Toxicol Rep       Date:  2014
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.